Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in East Asian ROS1+ NSCLC
NCT01945021Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2013
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Objective Response Rate at 94.0 weeks. Started Sep 2013; status: completed.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01945021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01945021.